Notably, mammalian SOD1 has been explored as a cancer therapeutic target for the selective killing of cancer cells with defective HR genes, such as BLM or RAD54B (Sajesh et al. 2013; Sajesh and McManus 2015). The gene discussed is BLM; the disease is cancer.